Your browser doesn't support javascript.
loading
The pharmacology of the prostaglandin D2 receptor 2 (DP2) receptor antagonist, fevipiprant.
Brightling, Chris; Kulkarni, Swarupa; Lambrecht, Bart N; Sandham, David; Weiss, Markus; Altman, Pablo.
Afiliación
  • Brightling C; Department of Respiratory Science, NIHR Biomedical Research Centre, Institute for Lung Health University of Leicester, Leicester, LE3 9QP, UK. Electronic address: ceb17@leicester.ac.uk.
  • Kulkarni S; Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ, 07936, USA.
  • Lambrecht BN; Laboratory of Immunoregulation, VIB Center for Inflammation Research, Ghent, Belgium; Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium; Department of Pulmonary Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Sandham D; Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge, MA, 02139, USA.
  • Weiss M; Novartis Institutes for Biomedical Research, Fabrikstrasse 2, Novartis Campus, CH-4056, Basel, Switzerland.
  • Altman P; Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ, 07936, USA.
Pulm Pharmacol Ther ; 68: 102030, 2021 06.
Article en En | MEDLINE | ID: mdl-33826946

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Calidad de Vida / Preparaciones Farmacéuticas Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Pulm Pharmacol Ther Asunto de la revista: FARMACOLOGIA Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Calidad de Vida / Preparaciones Farmacéuticas Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Pulm Pharmacol Ther Asunto de la revista: FARMACOLOGIA Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido